Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum non-SERCA-type Ca2+ -transporting P-ATPase

Ligand: PA21A092 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pEC50
Reference (Journal): Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.
Published in: Nat Commun

Ligand: MMV897698 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.420000076293945 pIC50
Reference (Journal): Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source Antimalarials.
Published in: J Med Chem

Ligand: MMV1803022 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.340000152587891 pIC50
Reference (Journal): An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel Antimalarials.
Published in: J Med Chem

Ligand: GSK030 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pIC50
Reference (Patent): Thiotriazole compound and its use in parasitic protozoal infections

Ligand: compound 1a [WO2021204952A1] (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pEC50
Reference (Patent): New anti-malarial agents

Ligand: compound 1a [WO2021204952A1] (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): New anti-malarial agents

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.850000381469727 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science